<p>I have read with great interest the Xiao et al. study examining retrospectively the incidence of falls and related factors in outpatient and inpatient elderly sample (<i>n</i> = 451) aged 65 years and above.<span><sup>1</sup></span> Key factors considered in the study were pain and other comorbidities, such as frailty and osteoarthritis.<span><sup>1</sup></span> Although the findings have great merits and add to the body of literature, there are some limitations that should have been addressed or reported in the study.</p><p>Whereas Xiao et al. data indicate that the association between pain and fall is not statistically significant, this finding was not explicitly presented in the article. More importantly, it is astounding that the study found pain had no impact on the incidence of falls, despite the clear link between pain and falls in older adults in the literature. For example, a 2014 systematic review and meta-analysis by Stubbs et al.<span><sup>2</sup></span> found that pain was associated with a higher risk of falls, where half (50.5%) of older adults with pain reported at least one fall over a 12-month period. A more recent systematic review found that multisite pain is associated with an increased risk of future falls risk in community-dwelling older people.<span><sup>3</sup></span> Further, it is well recognized that chronic pain is highly prevalent and disabling in older adults with and without dementia, but it is often an underestimated clinical problem in this population.<span><sup>4</sup></span> Given that the data in the Xiao et al. study did not involve the pathological state of “chronic pain,” and the latter differs from the concept of pain within 4 weeks, the authors cannot be assertive in concluding that pain had no impact on the incidence of falls. Clearly, the status, duration, and type of pain (e.g., acute nociceptive pain vs. persistent pain) may have influenced these findings and, therefore, the definition of pain should have been further clarified or operationalized in the Xiao et al. study. Moreover, the limitations of the study should have been mentioned that the findings were only applicable to this operational definition of pain.</p><p>The sample in the Xiao et al. study included older adults with mild and moderate dementia, whose pain reporting in some may be unreliable or inadequate. Further, the Mini-Mental State Examination instrument was listed in the methodology, but cognition scores were not reported for the sample. Thus, how did the authors ascertain intact cognition and communication skills in the sample? That is, how was the self-reporting capacity of the sample confirmed? If not, why was this not reported in the limitations?</p><p>Given that no difference in pain was detected between the fall and nonfall groups by the digital pain drawings instrument and this instrument was not validated in people with dementia, these issues raise the question whether the instrument was sensitive enough to detect any di
{"title":"Pain is underestimated in older adults with risk of falls","authors":"Mustafa Atee","doi":"10.1002/agm2.12283","DOIUrl":"https://doi.org/10.1002/agm2.12283","url":null,"abstract":"<p>I have read with great interest the Xiao et al. study examining retrospectively the incidence of falls and related factors in outpatient and inpatient elderly sample (<i>n</i> = 451) aged 65 years and above.<span><sup>1</sup></span> Key factors considered in the study were pain and other comorbidities, such as frailty and osteoarthritis.<span><sup>1</sup></span> Although the findings have great merits and add to the body of literature, there are some limitations that should have been addressed or reported in the study.</p><p>Whereas Xiao et al. data indicate that the association between pain and fall is not statistically significant, this finding was not explicitly presented in the article. More importantly, it is astounding that the study found pain had no impact on the incidence of falls, despite the clear link between pain and falls in older adults in the literature. For example, a 2014 systematic review and meta-analysis by Stubbs et al.<span><sup>2</sup></span> found that pain was associated with a higher risk of falls, where half (50.5%) of older adults with pain reported at least one fall over a 12-month period. A more recent systematic review found that multisite pain is associated with an increased risk of future falls risk in community-dwelling older people.<span><sup>3</sup></span> Further, it is well recognized that chronic pain is highly prevalent and disabling in older adults with and without dementia, but it is often an underestimated clinical problem in this population.<span><sup>4</sup></span> Given that the data in the Xiao et al. study did not involve the pathological state of “chronic pain,” and the latter differs from the concept of pain within 4 weeks, the authors cannot be assertive in concluding that pain had no impact on the incidence of falls. Clearly, the status, duration, and type of pain (e.g., acute nociceptive pain vs. persistent pain) may have influenced these findings and, therefore, the definition of pain should have been further clarified or operationalized in the Xiao et al. study. Moreover, the limitations of the study should have been mentioned that the findings were only applicable to this operational definition of pain.</p><p>The sample in the Xiao et al. study included older adults with mild and moderate dementia, whose pain reporting in some may be unreliable or inadequate. Further, the Mini-Mental State Examination instrument was listed in the methodology, but cognition scores were not reported for the sample. Thus, how did the authors ascertain intact cognition and communication skills in the sample? That is, how was the self-reporting capacity of the sample confirmed? If not, why was this not reported in the limitations?</p><p>Given that no difference in pain was detected between the fall and nonfall groups by the digital pain drawings instrument and this instrument was not validated in people with dementia, these issues raise the question whether the instrument was sensitive enough to detect any di","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"7 1","pages":"136-137"},"PeriodicalIF":0.0,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.12283","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140340268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aims to describe temporal trends of thyroid cancer (ThC) from 2010 to 2019, in Asian countries by geographical region and sociodemographic index, compared with global data.Annual case data and age‐standardized rates (ASRs) of epidemiological indicators of ThC cancer data were collected from the 2019 Global Burden of Disease (GBD) study from 2010 to 2019 in 49 countries and territories in Asia. The relative difference (%) between years was used to show comparative variations of ASRs for the indicators studied. The female/male ratio was calculated by dividing female ASRs by male ASRs. Also, these rates were compared between the age group ≥70 years old and younger age groups.In 2019, more than 50% of ThC cases and deaths occurred in Asian countries. A total of 53% of ThC patients lived in Asia and more than 60% of the global burden of ThC was imposed on Asian countries. From 2010 to 2019, incidences, deaths, prevalence cases, and DALYs number of ThC cancer increased over 1.28‐, 1.26‐, 1.3‐, and 1.2‐fold, in Asia, respectively. During this period, the age‐standardized incidence rate (ASIR) and the age‐standardized prevalence rate (ASPR) of ThC cancer increased by 5% and 8%, respectively, while the age‐standardized death rate (ASDR) and the age‐standardized DALYs rate (DALYs ASR) of ThC cancer decreased by 6% and 4%, respectively. These trends are different from what happens in other continents. In 2019, age‐specific incidence, death, prevalence, and DALY cases of ThC cancer were peaking at 50–54, 75–79, 50–54, and 55–59 years, respectively. In 2019, the highest ASIR and ASPR of ThC cancer was observed in high‐income Asia Pacific countries and the highest ASDR and DALYs ASR in Southeast Asia countries. Only high‐income Asia Pacific countries experienced a decreasing trend in ASIR and ASPR from 2010 to 2019. ASDR and DALYs ASR have the highest decreasing trend in high‐income Asia Pacific. In 2019, among high SDI Asian countries, the Republic of Korea had the highest ASIR and ASPR, and Brunei Darussalam had the highest ASDR and DALYs ASR. The highest ASIR, ASDR, ASPR, and DALY ASR of ThC cancer was found in Lebanon and Malaysia (high‐middle SDIs), Vietnam (middle SDIs), and Cambodia and Palestine (low‐middle SDIs). Among low SDI Asian countries, Pakistan had the highest ASIR, ASDR, ASPR, and DALY ASR of ThC cancer. All indicators for most countries were higher in women than men.More than half of the burden of thyroid cancer is imposed on the residents of the Asian continent. Although the incidence and prevalence of this cancer in Asian countries is lower than that of the world, America, and Europe, the highest rate of death from thyroid cancer occurs in Asia and they witness the highest burden of the disease. Therefore, it seems that implementing early detection strategies and increasing access to treatment facilities in Asia is one of the necessities of thyroid cancer control in its residents.
本研究旨在描述2010年至2019年亚洲各国甲状腺癌(ThC)按地理区域和社会人口指数划分的时间趋势,并与全球数据进行比较。从2019年全球疾病负担(GBD)研究中收集了2010年至2019年亚洲49个国家和地区甲状腺癌流行病学指标的年度病例数据和年龄标准化率(ASRs)。不同年份之间的相对差异(%)用于显示所研究指标的 ASRs 比较变化。女性/男性比率是用女性 ASR 除以男性 ASR 计算得出的。此外,还比较了≥70岁年龄组和更年轻年龄组之间的这些比率。2019年,50%以上的肺结核病例和死亡病例发生在亚洲国家。共有53%的肺结核患者生活在亚洲,全球60%以上的肺结核负担由亚洲国家承担。从 2010 年到 2019 年,亚洲的 ThC 癌症发病率、死亡人数、流行病例数和残疾调整生命年数分别增长了 1.28 倍、1.26 倍、1.3 倍和 1.2 倍。在此期间,THC 癌的年龄标准化发病率(ASIR)和年龄标准化患病率(ASPR)分别上升了 5%和 8%,而年龄标准化死亡率(ASDR)和年龄标准化残疾调整寿命年数(DALYs ASR)则分别下降了 6%和 4%。这些趋势与其他大洲的情况不同。2019年,特定年龄的肺癌发病率、死亡率、患病率和残疾调整寿命率分别在50-54岁、75-79岁、50-54岁和55-59岁达到峰值。2019 年,高收入亚太国家的 ThC 癌症 ASIR 和 ASPR 最高,东南亚国家的 ASDR 和 DALYs ASR 最高。从 2010 年到 2019 年,只有高收入亚太国家的 ASIR 和 ASPR 呈下降趋势。亚太地区高收入国家的 ASDR 和 DALYs ASR 下降趋势最高。2019 年,在 SDI 高的亚洲国家中,大韩民国的 ASIR 和 ASPR 最高,文莱达鲁萨兰国的 ASDR 和 DALYs ASR 最高。黎巴嫩和马来西亚(中高 SDIs)、越南(中 SDIs)以及柬埔寨和巴勒斯坦(中低 SDIs)的肺癌 ASIR、ASDR、ASPR 和 DALYs ASR 最高。在 SDI 较低的亚洲国家中,巴基斯坦的肺癌 ASIR、ASDR、ASPR 和 DALY ASR 最高。大多数国家的所有指标都是女性高于男性。虽然亚洲国家的甲状腺癌发病率和流行率低于世界、美洲和欧洲,但亚洲的甲状腺癌死亡率最高,疾病负担也最重。由此看来,在亚洲实施早期检测策略并增加治疗设施的可及性,是亚洲居民控制甲状腺癌的必要条件之一。
{"title":"Temporal trends of thyroid cancer between 2010 and 2019 in Asian countries by geographical region and SDI, comparison with global data","authors":"Fatemeh Rezaei, Afrooz Mazidimoradi, Zahra Pasokh, Seyed Parsa Dehghani, L. Allahqoli, Hamid Salehiniya","doi":"10.1002/agm2.12277","DOIUrl":"https://doi.org/10.1002/agm2.12277","url":null,"abstract":"This study aims to describe temporal trends of thyroid cancer (ThC) from 2010 to 2019, in Asian countries by geographical region and sociodemographic index, compared with global data.Annual case data and age‐standardized rates (ASRs) of epidemiological indicators of ThC cancer data were collected from the 2019 Global Burden of Disease (GBD) study from 2010 to 2019 in 49 countries and territories in Asia. The relative difference (%) between years was used to show comparative variations of ASRs for the indicators studied. The female/male ratio was calculated by dividing female ASRs by male ASRs. Also, these rates were compared between the age group ≥70 years old and younger age groups.In 2019, more than 50% of ThC cases and deaths occurred in Asian countries. A total of 53% of ThC patients lived in Asia and more than 60% of the global burden of ThC was imposed on Asian countries. From 2010 to 2019, incidences, deaths, prevalence cases, and DALYs number of ThC cancer increased over 1.28‐, 1.26‐, 1.3‐, and 1.2‐fold, in Asia, respectively. During this period, the age‐standardized incidence rate (ASIR) and the age‐standardized prevalence rate (ASPR) of ThC cancer increased by 5% and 8%, respectively, while the age‐standardized death rate (ASDR) and the age‐standardized DALYs rate (DALYs ASR) of ThC cancer decreased by 6% and 4%, respectively. These trends are different from what happens in other continents. In 2019, age‐specific incidence, death, prevalence, and DALY cases of ThC cancer were peaking at 50–54, 75–79, 50–54, and 55–59 years, respectively. In 2019, the highest ASIR and ASPR of ThC cancer was observed in high‐income Asia Pacific countries and the highest ASDR and DALYs ASR in Southeast Asia countries. Only high‐income Asia Pacific countries experienced a decreasing trend in ASIR and ASPR from 2010 to 2019. ASDR and DALYs ASR have the highest decreasing trend in high‐income Asia Pacific. In 2019, among high SDI Asian countries, the Republic of Korea had the highest ASIR and ASPR, and Brunei Darussalam had the highest ASDR and DALYs ASR. The highest ASIR, ASDR, ASPR, and DALY ASR of ThC cancer was found in Lebanon and Malaysia (high‐middle SDIs), Vietnam (middle SDIs), and Cambodia and Palestine (low‐middle SDIs). Among low SDI Asian countries, Pakistan had the highest ASIR, ASDR, ASPR, and DALY ASR of ThC cancer. All indicators for most countries were higher in women than men.More than half of the burden of thyroid cancer is imposed on the residents of the Asian continent. Although the incidence and prevalence of this cancer in Asian countries is lower than that of the world, America, and Europe, the highest rate of death from thyroid cancer occurs in Asia and they witness the highest burden of the disease. Therefore, it seems that implementing early detection strategies and increasing access to treatment facilities in Asia is one of the necessities of thyroid cancer control in its residents.","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"5 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139440000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Geriatric frailty determinants in India","authors":"Jorge Luis Passarelli, Hanadi Al Hamad","doi":"10.1002/agm2.12275","DOIUrl":"https://doi.org/10.1002/agm2.12275","url":null,"abstract":"","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"6 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139438843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell growth involves cell division. This stops after reaching a certain limit. Some cells become inactive and unable to undergo apoptosis (programmed cell death). These cells accumulate at sites of tissue damage or disease, thus accelerating aging. They are called senescent cells. Therapeutic interventions that can either eliminate senescent cells (senolytics) or suppress their harmful effects (senomorphics) have been developed. Senescence (aging) is caused by the inter‐ and intramolecular interactions between the domains of forkhead (FHD) and transactivation (TAD), as well as C‐terminal region 3 (CR3) and DNA binding (DBD). On the other hand, anti‐senescent/senolytic (anti‐aging) activities are achieved by disrupting these interactions with CR3‐ and forkhead box protein O4 (FOXO4)‐based peptides, such as ES2 and DRI, respectively. In this study, we use a computerized procedure based on digital signal processing to systematically analyze the inter‐molecular interactions between senolytics and their targets.Informational spectrum method (ISM) is engaged.We obtained the sequences of the peptides from the interacting proteins of CR3 and FOXO4 and evaluated their ability to disrupt the inter‐molecular interactions between FOXO4 and DRI and CR3 and BDB, which are responsible for senescence (aging). Our results show that the peptides have different degrees of senolytic (anti‐aging) activity, depending on their affinity for CR3 and BDB, or FOXO4 and DRI. We found that enhanced senescence 2 (ES2) has a higher affinity for CR3 and BDB than FOXO4 and DRI, and that the interaction between CR3 and BDB is crucial for aging. Therefore, ES2 and other CR3‐based peptides are more potent senolytics than FOXO4‐based peptides. Our findings are consistent with previous studies and reveal new insights into the mechanisms of senescence and senolytics. ES2 is considered the best senolytic candidate, as it is 3–7 times more effective than DRI. We verified that ES2 has a weaker interaction with FOXO4 than CR3. However, the performance of DRI has been noted to depend on its intramolecular interactions and stability. Hence, intramolecular analyses using the digital signal processing‐based technique has become very vital and will follow.CR3‐based peptides are promising candidates for senolytic therapy. Senolytics are linear chains of amino acids that can target and eliminate senescent cells, which are cells that have stopped dividing and contribute to aging and age‐related diseases. By using this proposed, novel computerized technique that is based on digital signal processing, senolytics can be easily analyzed and optimized for their effectiveness and safety. This provides a more rational approach to enhancing our longevity and well‐being by offering interventions that can delay or reverse aging and insights that can advance the field of gerontology. This procedure also will compliment other approaches such as molecular stimulation, etc.
{"title":"Bioinformatics procedure for investigating senolytic (anti‐aging) agents: A digital signal processing technique","authors":"Norbert Nwankwo, Ignatius Okafor","doi":"10.1002/agm2.12274","DOIUrl":"https://doi.org/10.1002/agm2.12274","url":null,"abstract":"Cell growth involves cell division. This stops after reaching a certain limit. Some cells become inactive and unable to undergo apoptosis (programmed cell death). These cells accumulate at sites of tissue damage or disease, thus accelerating aging. They are called senescent cells. Therapeutic interventions that can either eliminate senescent cells (senolytics) or suppress their harmful effects (senomorphics) have been developed. Senescence (aging) is caused by the inter‐ and intramolecular interactions between the domains of forkhead (FHD) and transactivation (TAD), as well as C‐terminal region 3 (CR3) and DNA binding (DBD). On the other hand, anti‐senescent/senolytic (anti‐aging) activities are achieved by disrupting these interactions with CR3‐ and forkhead box protein O4 (FOXO4)‐based peptides, such as ES2 and DRI, respectively. In this study, we use a computerized procedure based on digital signal processing to systematically analyze the inter‐molecular interactions between senolytics and their targets.Informational spectrum method (ISM) is engaged.We obtained the sequences of the peptides from the interacting proteins of CR3 and FOXO4 and evaluated their ability to disrupt the inter‐molecular interactions between FOXO4 and DRI and CR3 and BDB, which are responsible for senescence (aging). Our results show that the peptides have different degrees of senolytic (anti‐aging) activity, depending on their affinity for CR3 and BDB, or FOXO4 and DRI. We found that enhanced senescence 2 (ES2) has a higher affinity for CR3 and BDB than FOXO4 and DRI, and that the interaction between CR3 and BDB is crucial for aging. Therefore, ES2 and other CR3‐based peptides are more potent senolytics than FOXO4‐based peptides. Our findings are consistent with previous studies and reveal new insights into the mechanisms of senescence and senolytics. ES2 is considered the best senolytic candidate, as it is 3–7 times more effective than DRI. We verified that ES2 has a weaker interaction with FOXO4 than CR3. However, the performance of DRI has been noted to depend on its intramolecular interactions and stability. Hence, intramolecular analyses using the digital signal processing‐based technique has become very vital and will follow.CR3‐based peptides are promising candidates for senolytic therapy. Senolytics are linear chains of amino acids that can target and eliminate senescent cells, which are cells that have stopped dividing and contribute to aging and age‐related diseases. By using this proposed, novel computerized technique that is based on digital signal processing, senolytics can be easily analyzed and optimized for their effectiveness and safety. This provides a more rational approach to enhancing our longevity and well‐being by offering interventions that can delay or reverse aging and insights that can advance the field of gerontology. This procedure also will compliment other approaches such as molecular stimulation, etc.","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"54 13","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139447567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}